Cardiovascular manifestation and treatment in COVID-19.
Identifieur interne : 001640 ( Main/Corpus ); précédent : 001639; suivant : 001641Cardiovascular manifestation and treatment in COVID-19.
Auteurs : Yen-Bo Su ; Ming-Jen Kuo ; Ting-Yu Lin ; Chian-Shiu Chien ; Yi-Ping Yang ; Shih-Jie Chou ; Hsin-Bang LeuSource :
- Journal of the Chinese Medical Association : JCMA [ 1728-7731 ] ; 2020.
English descriptors
- KwdEn :
- Anticoagulants (therapeutic use), Antiviral Agents (therapeutic use), Betacoronavirus (MeSH), COVID-19 (MeSH), Cardiovascular Diseases (etiology), Coronavirus Infections (complications), Coronavirus Infections (drug therapy), Humans (MeSH), Hydroxychloroquine (therapeutic use), Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use), Pandemics (MeSH), Pneumonia, Viral (complications), Pneumonia, Viral (drug therapy), SARS-CoV-2 (MeSH).
- MESH :
- chemical , therapeutic use : Anticoagulants, Antiviral Agents, Hydroxychloroquine, Hydroxymethylglutaryl-CoA Reductase Inhibitors.
- complications : Coronavirus Infections, Pneumonia, Viral.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- etiology : Cardiovascular Diseases.
- Betacoronavirus, COVID-19, Humans, Pandemics, SARS-CoV-2.
Abstract
The novel coronavirus disease 2019 (COVID-19), with first presentation of atypical pneumonia, has spread rapidly from Wuhan, China, on December 12, 2019 to over 200 countries, caused 2 310 572 infected individuals and 158 691 mortalities, updated on April 19, 2020. Many studies have published timely to help global healthcare workers to understand and control the disease. Vulnerable patients with risk factors such as elderly, cardiovascular diseases (eg, hypertension, coronary disease, or cardiomyopathy), diabetes, and chronic kidney disease have worse outcomes after COVID-19 infection. COVID-19 could directly cause cardiovascular injuries such as pericarditis, myocarditis, myocardial infarction, heart failure, arrhythmias, or thromboembolic events, which urge cardiologists to be involved in the frontline to practice. Here, we provide a review of COVID-19 on cardiovascular system to assist clinical cardiologists to better understand the disease and being capable of providing comprehensive medical support.
DOI: 10.1097/JCMA.0000000000000352
PubMed: 32433342
PubMed Central: PMC7493780
Links to Exploration step
pubmed:32433342Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cardiovascular manifestation and treatment in COVID-19.</title><author><name sortKey="Su, Yen Bo" sort="Su, Yen Bo" uniqKey="Su Y" first="Yen-Bo" last="Su">Yen-Bo Su</name><affiliation><nlm:affiliation>Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Cardiovascular Research Center, National Yang-Ming University, Taipei, Taiwan, ROC.</nlm:affiliation></affiliation></author><author><name sortKey="Kuo, Ming Jen" sort="Kuo, Ming Jen" uniqKey="Kuo M" first="Ming-Jen" last="Kuo">Ming-Jen Kuo</name><affiliation><nlm:affiliation>Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Cardiovascular Research Center, National Yang-Ming University, Taipei, Taiwan, ROC.</nlm:affiliation></affiliation></author><author><name sortKey="Lin, Ting Yu" sort="Lin, Ting Yu" uniqKey="Lin T" first="Ting-Yu" last="Lin">Ting-Yu Lin</name><affiliation><nlm:affiliation>Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Cardiovascular Research Center, National Yang-Ming University, Taipei, Taiwan, ROC.</nlm:affiliation></affiliation></author><author><name sortKey="Chien, Chian Shiu" sort="Chien, Chian Shiu" uniqKey="Chien C" first="Chian-Shiu" last="Chien">Chian-Shiu Chien</name><affiliation><nlm:affiliation>Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</nlm:affiliation></affiliation></author><author><name sortKey="Yang, Yi Ping" sort="Yang, Yi Ping" uniqKey="Yang Y" first="Yi-Ping" last="Yang">Yi-Ping Yang</name><affiliation><nlm:affiliation>Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</nlm:affiliation></affiliation></author><author><name sortKey="Chou, Shih Jie" sort="Chou, Shih Jie" uniqKey="Chou S" first="Shih-Jie" last="Chou">Shih-Jie Chou</name><affiliation><nlm:affiliation>Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</nlm:affiliation></affiliation></author><author><name sortKey="Leu, Hsin Bang" sort="Leu, Hsin Bang" uniqKey="Leu H" first="Hsin-Bang" last="Leu">Hsin-Bang Leu</name><affiliation><nlm:affiliation>Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Cardiovascular Research Center, National Yang-Ming University, Taipei, Taiwan, ROC.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Healthcare and Service Center, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32433342</idno><idno type="pmid">32433342</idno><idno type="doi">10.1097/JCMA.0000000000000352</idno><idno type="pmc">PMC7493780</idno><idno type="wicri:Area/Main/Corpus">001640</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001640</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cardiovascular manifestation and treatment in COVID-19.</title><author><name sortKey="Su, Yen Bo" sort="Su, Yen Bo" uniqKey="Su Y" first="Yen-Bo" last="Su">Yen-Bo Su</name><affiliation><nlm:affiliation>Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Cardiovascular Research Center, National Yang-Ming University, Taipei, Taiwan, ROC.</nlm:affiliation></affiliation></author><author><name sortKey="Kuo, Ming Jen" sort="Kuo, Ming Jen" uniqKey="Kuo M" first="Ming-Jen" last="Kuo">Ming-Jen Kuo</name><affiliation><nlm:affiliation>Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Cardiovascular Research Center, National Yang-Ming University, Taipei, Taiwan, ROC.</nlm:affiliation></affiliation></author><author><name sortKey="Lin, Ting Yu" sort="Lin, Ting Yu" uniqKey="Lin T" first="Ting-Yu" last="Lin">Ting-Yu Lin</name><affiliation><nlm:affiliation>Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Cardiovascular Research Center, National Yang-Ming University, Taipei, Taiwan, ROC.</nlm:affiliation></affiliation></author><author><name sortKey="Chien, Chian Shiu" sort="Chien, Chian Shiu" uniqKey="Chien C" first="Chian-Shiu" last="Chien">Chian-Shiu Chien</name><affiliation><nlm:affiliation>Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</nlm:affiliation></affiliation></author><author><name sortKey="Yang, Yi Ping" sort="Yang, Yi Ping" uniqKey="Yang Y" first="Yi-Ping" last="Yang">Yi-Ping Yang</name><affiliation><nlm:affiliation>Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</nlm:affiliation></affiliation></author><author><name sortKey="Chou, Shih Jie" sort="Chou, Shih Jie" uniqKey="Chou S" first="Shih-Jie" last="Chou">Shih-Jie Chou</name><affiliation><nlm:affiliation>Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</nlm:affiliation></affiliation></author><author><name sortKey="Leu, Hsin Bang" sort="Leu, Hsin Bang" uniqKey="Leu H" first="Hsin-Bang" last="Leu">Hsin-Bang Leu</name><affiliation><nlm:affiliation>Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Cardiovascular Research Center, National Yang-Ming University, Taipei, Taiwan, ROC.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Healthcare and Service Center, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Journal of the Chinese Medical Association : JCMA</title><idno type="eISSN">1728-7731</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anticoagulants (therapeutic use)</term><term>Antiviral Agents (therapeutic use)</term><term>Betacoronavirus (MeSH)</term><term>COVID-19 (MeSH)</term><term>Cardiovascular Diseases (etiology)</term><term>Coronavirus Infections (complications)</term><term>Coronavirus Infections (drug therapy)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (complications)</term><term>Pneumonia, Viral (drug therapy)</term><term>SARS-CoV-2 (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anticoagulants</term><term>Antiviral Agents</term><term>Hydroxychloroquine</term><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Cardiovascular Diseases</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>COVID-19</term><term>Humans</term><term>Pandemics</term><term>SARS-CoV-2</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The novel coronavirus disease 2019 (COVID-19), with first presentation of atypical pneumonia, has spread rapidly from Wuhan, China, on December 12, 2019 to over 200 countries, caused 2 310 572 infected individuals and 158 691 mortalities, updated on April 19, 2020. Many studies have published timely to help global healthcare workers to understand and control the disease. Vulnerable patients with risk factors such as elderly, cardiovascular diseases (eg, hypertension, coronary disease, or cardiomyopathy), diabetes, and chronic kidney disease have worse outcomes after COVID-19 infection. COVID-19 could directly cause cardiovascular injuries such as pericarditis, myocarditis, myocardial infarction, heart failure, arrhythmias, or thromboembolic events, which urge cardiologists to be involved in the frontline to practice. Here, we provide a review of COVID-19 on cardiovascular system to assist clinical cardiologists to better understand the disease and being capable of providing comprehensive medical support.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32433342</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1728-7731</ISSN><JournalIssue CitedMedium="Internet"><Volume>83</Volume><Issue>8</Issue><PubDate><Year>2020</Year><Month>08</Month></PubDate></JournalIssue><Title>Journal of the Chinese Medical Association : JCMA</Title><ISOAbbreviation>J Chin Med Assoc</ISOAbbreviation></Journal><ArticleTitle>Cardiovascular manifestation and treatment in COVID-19.</ArticleTitle><Pagination><MedlinePgn>704-709</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/JCMA.0000000000000352</ELocationID><Abstract><AbstractText>The novel coronavirus disease 2019 (COVID-19), with first presentation of atypical pneumonia, has spread rapidly from Wuhan, China, on December 12, 2019 to over 200 countries, caused 2 310 572 infected individuals and 158 691 mortalities, updated on April 19, 2020. Many studies have published timely to help global healthcare workers to understand and control the disease. Vulnerable patients with risk factors such as elderly, cardiovascular diseases (eg, hypertension, coronary disease, or cardiomyopathy), diabetes, and chronic kidney disease have worse outcomes after COVID-19 infection. COVID-19 could directly cause cardiovascular injuries such as pericarditis, myocarditis, myocardial infarction, heart failure, arrhythmias, or thromboembolic events, which urge cardiologists to be involved in the frontline to practice. Here, we provide a review of COVID-19 on cardiovascular system to assist clinical cardiologists to better understand the disease and being capable of providing comprehensive medical support.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Yen-Bo</ForeName><Initials>YB</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Research Center, National Yang-Ming University, Taipei, Taiwan, ROC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuo</LastName><ForeName>Ming-Jen</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Research Center, National Yang-Ming University, Taipei, Taiwan, ROC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Ting-Yu</ForeName><Initials>TY</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Research Center, National Yang-Ming University, Taipei, Taiwan, ROC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chien</LastName><ForeName>Chian-Shiu</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yi-Ping</ForeName><Initials>YP</Initials><AffiliationInfo><Affiliation>Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chou</LastName><ForeName>Shih-Jie</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leu</LastName><ForeName>Hsin-Bang</ForeName><Initials>HB</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Research Center, National Yang-Ming University, Taipei, Taiwan, ROC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Healthcare and Service Center, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Chin Med Assoc</MedlineTA><NlmUniqueID>101174817</NlmUniqueID><ISSNLinking>1726-4901</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="N">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32433342</ArticleId><ArticleId IdType="doi">10.1097/JCMA.0000000000000352</ArticleId><ArticleId IdType="pmc">PMC7493780</ArticleId><ArticleId IdType="pii">02118582-202008000-00007</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020;181:281–92.e6.</Citation></Reference><Reference><Citation>Landi A, Iannucci V, Nuffel AV, Meuwissen P, Verhasselt B. One protein to rule them all: modulation of cell surface receptors and molecules by HIV Nef. Curr HIV Res 2011;9:496–504.</Citation></Reference><Reference><Citation>Fisman DN. Hemophagocytic syndromes and infection. Emerg Infect Dis 2000;6:601–8.</Citation></Reference><Reference><Citation>Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Bondi-Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol 2020;75:2352–71.</Citation></Reference><Reference><Citation>Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. Coronavirus disease 2019 (COVID-19) and cardiovascular disease. Circulation 2020;141:1648–55.</Citation></Reference><Reference><Citation>Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol 2020Doi:10.1001/jamacardio.2020.1286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.1286</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonow RO, Fonarow GC, O’Gara PT, Yancy CW. Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality. JAMA Cardiol 2020Doi:10.1001/jamacardio.2020.1105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.1105</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu PP, Blet A, Smyth D, Li H. The science underlying COVID-19: implications for the cardiovascular system. Circulation 2020;142:68–78.</Citation></Reference><Reference><Citation>Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020;8:475–81.</Citation></Reference><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.</Citation></Reference><Reference><Citation>Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020;382:1199–207.</Citation></Reference><Reference><Citation>Flahault A. Has China faced only a herald wave of SARS-CoV-2? Lancet 2020;395:947.</Citation></Reference><Reference><Citation>Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China. Euro Surveill 2020;25:2000062.</Citation></Reference><Reference><Citation>Hosseiny M, Kooraki S, Gholamrezanezhad A, Reddy S, Myers L. Radiology perspective of coronavirus disease 2019 (COVID-19): lessons from severe acute respiratory syndrome and middle east respiratory syndrome. AJR Am J Roentgenol 2020;214:1–5.</Citation></Reference><Reference><Citation>Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382:1708–20.</Citation></Reference><Reference><Citation>Madjid M, Miller CC, Zarubaev VV, Marinich IG, Kiselev OI, Lobzin YV, et al. Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects. Eur Heart J 2007;28:1205–10.</Citation></Reference><Reference><Citation>Cowan LT, Lutsey PL, Pankow JS, Matsushita K, Ishigami J, Lakshminarayan K. Inpatient and outpatient infection as a trigger of cardiovascular disease: The ARIC Study. J Am Heart Assoc 2018;7:e009683.</Citation></Reference><Reference><Citation>Dhainaut JF, Claessens YE, Janes J, Nelson DR. Underlying disorders and their impact on the host response to infection. Clin Infect Dis 2005;41Suppl 7S481–9.</Citation></Reference><Reference><Citation>Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020Doi:10.1001/jamacardio.2020.0950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.0950</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020Doi:10.1001/jamacardio.2020.1017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.1017</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. COVID-19 in critically ill patients in the Seattle region: case series. N Engl J Med 2020;382:2012–22.</Citation></Reference><Reference><Citation>Bangalore S, Sharma A, Slotwiner A, Yatskar L, Harari R, Shah B, et al. ST-segment elevation in patients with COVID-19: a case series. N Engl J Med 2020Doi:10.1056/NEJMc2009020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2009020</ArticleId></ArticleIdList></Reference><Reference><Citation>Welt FGP, Shah PB, Aronow HD, Bortnick AE, Henry TD, Sherwood MW, et al. Catheterization laboratory considerations during the coronavirus (COVID-19) pandemic: from the ACC’s Interventional Council and SCAI. J Am Coll Cardiol 2020;75:2372–5.</Citation></Reference><Reference><Citation>Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol 2020Doi:10.1016/j.jacc.2020.04.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.04.031</ArticleId></ArticleIdList></Reference><Reference><Citation>Madjid M, Casscells SW. Of birds and men: cardiologists’ role in influenza pandemics. Lancet 2004;364:1309.</Citation></Reference><Reference><Citation>Madjid M, Aboshady I, Awan I, Litovsky S, Casscells SW. Influenza and cardiovascular disease: is there a causal relationship? Tex Heart Inst J 2004;31:4–13.</Citation></Reference><Reference><Citation>Vardeny O, Solomon SD. Influenza vaccination: a one-shot deal to reduce cardiovascular events. Eur Heart J 2017;38:334–7.</Citation></Reference><Reference><Citation>Wang EY, Hulme OL, Khurshid S, Weng LC, Choi SH, Walkey AJ, et al. Initial precipitants and recurrence of atrial fibrillation. Circ Arrhythm Electrophysiol 2020;13:e007716.</Citation></Reference><Reference><Citation>Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020;18:844–7.</Citation></Reference><Reference><Citation>Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020Doi:10.1001/jamacardio.2020.1096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.1096</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8:420–2.</Citation></Reference><Reference><Citation>Tavazzi G, Pellegrini C, Maurelli M, Belliato M, Sciutti F, Bottazzi A, et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail 2020;22:911–5.</Citation></Reference><Reference><Citation>Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269–71.</Citation></Reference><Reference><Citation>Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of remdesivir for patients with severe COVID-19. N Engl J Med 2020Doi:10.1056/NEJMoa2007016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2007016</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 2020;382:1787–99.</Citation></Reference><Reference><Citation>Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061–9.</Citation></Reference><Reference><Citation>Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 2020;14:58–60.</Citation></Reference><Reference><Citation>Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering 2020Doi:10.1016/j.eng.2020.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eng.2020.03.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. medRxiv. 2020Doi:10.1101/2020.03.17.20037432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.03.17.20037432</ArticleId></ArticleIdList></Reference><Reference><Citation>Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis 2003;3:722–7.</Citation></Reference><Reference><Citation>Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020Doi:10.1093/cid/ciaa237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa237</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020Doi:10.1016/j.ijantimicag.2020.105949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.105949</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020;14:72–3.</Citation></Reference><Reference><Citation>Principi N, Esposito S. Chloroquine or hydroxychloroquine for prophylaxis of COVID-19. Lancet Infect Dis 2020Doi:10.1016/S1473-3099(20)30296-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30296-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers YM. Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature. Drug Saf 2018;41:919–31.</Citation></Reference><Reference><Citation>Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 2005;11:875–9.</Citation></Reference><Reference><Citation>Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19. N Engl J Med 2020;382:1653–9.</Citation></Reference><Reference><Citation>Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020Doi:10.1161/CIRCRESAHA.120.317134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.120.317134</ArticleId></ArticleIdList></Reference><Reference><Citation>Sexton TR, Zhang G, Macaulay TE, Callahan LA, Charnigo R, Vsevolozhskaya OA, et al. Ticagrelor reduces thromboinflammatory markers in patients with pneumonia. JACC Basic Transl Sci 2018;3:435–49.</Citation></Reference><Reference><Citation>Storey RF, James SK, Siegbahn A, Varenhorst C, Held C, Ycas J, et al. Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets 2014;25:517–25.</Citation></Reference><Reference><Citation>Yilmaz S, Kiliç O, Yaylali YT. Diffuse alveolar hemorrhage associated with ticagrelor therapy after percutaneous coronary intervention. Anatol J Cardiol 2018;20:60–1.</Citation></Reference><Reference><Citation>Toyota T, Shiomi H, Morimoto T, Natsuaki M, Kimura T. Short versus prolonged dual antiplatelet therapy (DAPT) duration after coronary stent implantation: a comparison between the DAPT study and 9 other trials evaluating DAPT duration. PLoS One 2017;12:e0174502.</Citation></Reference><Reference><Citation>Zhou X, Li Y, Yang Q. Antiplatelet therapy following percutaneous coronary intervention in patients complicated by COVID-19: implications from clinical features to pathological findings. Circulation 2020;141:1736–8.</Citation></Reference><Reference><Citation>Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020;18:1023–6.</Citation></Reference><Reference><Citation>Wu C, Chen X, Cai Y, Xia Ja, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients With coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020Doi:10.1001/jamainternmed.2020.0994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.0994</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007;131:1006–12.</Citation></Reference><Reference><Citation>Vandermeer ML, Thomas AR, Kamimoto L, Reingold A, Gershman K, Meek J, et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J Infect Dis 2012;205:13–9.</Citation></Reference><Reference><Citation>Calfee CS, Delucchi KL, Sinha P, Matthay MA, Hackett J, Shankar-Hari M, et alIrish Critical Care Trials Group. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir Med 2018;6:691–8.</Citation></Reference><Reference><Citation>Novack V, MacFadyen J, Malhotra A, Almog Y, Glynn RJ, Ridker PM. The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial. CMAJ 2012;184:E367–72.</Citation></Reference><Reference><Citation>Ayman F, Ping W, Mahmoud A, Hesham S. Identification of FDA approved drugs targeting COVID-19 virus by structure-based drug repositioning. ChemRxiv 2020Doi:10.26434/chemrxiv.12003930.</Citation><ArticleIdList><ArticleId IdType="doi">10.26434/chemrxiv.12003930</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauvin B, Drouot S, Barrail-Tran A, Taburet AM. Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet 2013;52:815–31.</Citation></Reference><Reference><Citation>Hui H, Zhang Y, Yang X, Wang X, He B, Li L, et al. Clinical and radiographic features of cardiac injury in patients with 2019 novel coronavirus pneumonia. medRxiv 2020Doi:10.1101/2020.02.24.20027052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.02.24.20027052</ArticleId></ArticleIdList></Reference><Reference><Citation>Stadler K, Ha HR, Ciminale V, Spirli C, Saletti G, Schiavon M, et al. Amiodarone alters late endosomes and inhibits SARS coronavirus infection at a post-endosomal level. Am J Respir Cell Mol Biol 2008;39:142–9.</Citation></Reference><Reference><Citation>Kawaguchi M, Takahashi M, Hata T, Kashima Y, Usui F, Morimoto H, et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation 2011;123:594–604.</Citation></Reference><Reference><Citation>Demidowich AP, Davis AI, Dedhia N, Yanovski JA. Colchicine to decrease NLRP3-activated inflammation and improve obesity-related metabolic dysregulation. Med Hypotheses 2016;92:67–73.</Citation></Reference><Reference><Citation>Cocchi E, Chiale F, Gianoglio B, Deorsola L, Pace Napoleone C, Fagioli F, et al. Colchicine: an impressive effect on posttransplant capillary leak syndrome and renal failure. Pediatrics 2019;143:e20182820.</Citation></Reference><Reference><Citation>Misawa T, Takahama M, Kozaki T, Lee H, Zou J, Saitoh T, et al. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol 2013;14:454–60.</Citation></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001640 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001640 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32433342
|texte= Cardiovascular manifestation and treatment in COVID-19.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32433342" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |